Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 47
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/26/2007
1.
Phase III Chemohormonal Therapy with ADR/CCNU/VCR/FXM vs CTX/MPA plus Immunotherapy with C. parvum for Metastatic Renal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
20 to 70
MSHMC-REN-2
Last Modified:
1/25/2008
 
First Published:
3/1/1997
2.
Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention, Treatment
Closed
18 and over
NCI
SWOG-S9630
CALGB-49901, SWOG-9630, S9630, NCT00002920
3.
CACP/HMM vs CACP/HMM/MPA for Advanced Epithelial Ovarian Tumor - A Phase III Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
NCI-D79-019-073
BUCRC-751
Last Modified:
3/19/2008
 
First Published:
11/1/2001
4.
Phase III Randomized Study of Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women With a History of Node-Negative Invasive Carcinoma or Ductal Carcinoma in Situ of the Breast Who are Receiving Adjuvant Tamoxifen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
NCI
E-2193
NCI-P01-0194, NCT00026286, ECOG-E2193
Last Modified:
11/30/2006
 
First Published:
2/1/2002
5.
Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
18 and over
NCI
NCCTG-N99C7
NCI-P02-0204, NCT00030914
6.
Phase III Percutaneous Transfemoral Renal Artery Occlusion, Nephrectomy and Hormonal Therapy with Medroxyprogesterone Acetate for Metastatic Renal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
MDA-U/u17
Last Modified:
11/1/1995
7.
Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
NCI
GOG-48
GOG-7941, GOG-48
8.
Phase III Postinfarction Nephrectomy plus Medroxyprogesterone Acetate for Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
no age specified
NCI
SWOG-7956
9.
Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 75
BGSM-89285
NCI-V85-0243
Last Modified:
8/1/1989
10.
Phase III Randomized Trial of Adjuvant Therapy with Medroxyprogesterone Acetate in Patients with High-Risk Endometrial Cancer (Summary Last Modified 08/89)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
any age
COSA-UK-NZ-E1/82
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute